Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Imaging MS from Shimadzu, Alzheimer's Markers from Proteome Sciences


Shimadzu this week announced the launch of its Imaging Mass Microscrope, iMScope, which combines optical microscopy and mass spectrometry in one instrument.

The device combines an optical microscope and hybrid ion trap time of flight mass spectrometer, allowing for observation of high resolution morphological images via microscopy and for identification and visualization of specific molecules via mass spec.

The device can visualize molecules with sub-cellular resolution, achieving resolution of 5 µm, and allows for analysis of living cells or tissue samples, the company said.

Proteome Sciences this week launched its Alzheimer's CSF 16-plex assay, a protein biomarker panel for simultaneously measuring 16 protein biomarkers in cerebrospinal fluid.

Using selected-reaction monitoring mass spec, the panel is intended for monitoring disease in Alzheimer's patients and could potentially be used as a diagnostic assay, the company said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.